Authors

Shreyaskumar Patel, MD, The University of Texas MD Anderson Cancer Center

Shreyaskumar R. Patel, MD, MD Anderson Cancer Center

Shreyaskumar R. Patel, MD, University of Texas MD Anderson Cancer Center

Shubham Pant, MD

Latest:

Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Shubham Pant, MD, MD Anderson Cancer Center

Latest:

TRK Inhibitors in Lung and GI Cancers

Shubham Pant, MD, The University of Texas MD Anderson Cancer Center

Shuo

Shuo Ma, MD, PhD, Feinberg School of Medicine at Northwestern Medicine

Shuo Ma, MD, PhD, Northwestern University Feinberg School of Medicine

Shuo Ma, MD, PhD, Northwestern University Feinberg School of Medicine, Susan M. O’Brien, MD, UC Irvine Health

Shuo Ma, MD, PhD, Robert H. Lurie Comprehensive Cancer Center

Shweta Gupta, MD

Latest:

Tricks of the Trade: 4 Decades of Wisdom

Medical oncology can be a very demanding and taxing field.

Siamak Daneshmand, MD

Latest:

Dr Daneschmand on Data From SunRISe-1 With TAR-200 and Cetrelimab in BCG-Unresponsive NMIBC

Sia Daneshmand MD, discusses preliminary results from the phase 2 SunRISe-1 trial (NCT04640623) in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Siavash Jabbari, MD

Latest:

Dr. Jabbari on the Potential for Implantable Cardiac Devices to Malfunction Following RT

Siavash Jabbari, MD, discusses the potential for implantable cardiac devices to malfunction following radiation therapy.

Sibel Blau, MD

Latest:

Dr. Blau on a Research-Based Approach to Meet OCM Requirements

Sibel Blau, MD, medical oncology provider, medical director, Hematology/Oncology, Northwest Medical Specialties, discusses a value-based care model for oncology at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Sibylle Loibl, MD, PhD

Latest:

Dr. Loibl Discusses GeparSepto Trial in Breast Cancer

Sibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.

Siddhartha Devarakonda, MD

Latest:

Dr. Devarakonda on Second-line Treatment Options in Small Cell Lung Cancer

Siddhartha Devarakonda, MD, MBBS, discusses second-line treatment considerations for patients with small cell lung cancer.

Sigrid Eckardt

Latest:

A Closer Look at BRAF Melanoma Testing Reveals Intricacies of V600 Mutation

BRAF mutation testing has become an essential tool in the diagnostic workup and management of patients with advanced melanoma. Activating mutations of BRAF are present in 40% to 60% of all melanoma cases, with more than 90% of mutations found at codon 600 in exon 15.

Silas Inman

Silas is the senior vice president, content, at MJH Life Sciences. He began his career at MJH in 2011 as a Web Editor on OncLive. From this role, he moved into managing the social media across the organization and then into broader roles across the content department, first taking on management of HCPLive.

Latest:

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Silvia Chiara Formenti, MD

Latest:

Dr. Formenti on Recent Progress With HER2-Targeted Therapy

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the recent progress with HER2-targeted therapy in the treatment of breast cancer.